Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3995
Single User License Price INR 293513
Corporate User License Price USD 11985
Corporate User License Price INR 880538
Site License Price USD 7990
Site License Price INR 587025
Request a Quote

Report Title

Hepatitis Drug Development Pipeline Review, 2018

Quote Request for License Type
License Type Price  
Single User License USD 3995
Site License USD 7990
Enterprise Wide License USD 11985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hepatitis Drug Development Pipeline Review, 2018


Quote Request for License Type
License Type Price  
Single User License USD 3995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hepatitis Drug Development Pipeline Review, 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hepatitis Drug Development Pipeline Review, 2018



Executive Summary

Hepatitis Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features dormant and discontinued products.

Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Hepatitis A and E are typically caused by ingestion of contaminated food or water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes.

Risk factors include a weakened immune system and use of injected or non-injected illicit drugs. Symptoms of hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite and pain in the abdomen.

Hepatitis B and hepatitis D infection typically occur as a result of contact with infected body fluids. Transmission of hepatitis B can occur via sexual contact, injection drug use or transfusions of contaminated blood and blood products. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting and abdominal pain.

Hepatitis D infection only occurs in persons previously infected with hepatitis B, as the hepatitis D virus can only replicate in the presence of hepatitis B. The co-infection of hepatitis B and hepatitis D is associated with greater disease severity than hepatitis B infection alone.

Companies operating in this pipeline space include Cadila Healthcare and Chongqing Zhifei Biological Products.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Hepatitis Report Coverage 8

2.2 Hepatitis A-Overview 8

2.3 Hepatitis B-Overview 8

2.4 Hepatitis D-Overview 8

2.5 Hepatitis E-Overview 8

3 Therapeutics Development 9

3.1 Hepatitis A 9

3.2 Hepatitis B 12

3.3 Hepatitis D 27

3.4 Hepatitis E 30

4 Therapeutics Assessment 33

4.1 Hepatitis A 33

4.2 Hepatitis B 35

4.3 Hepatitis D 44

4.4 Hepatitis E 49

5 Companies Involved in Therapeutics Development 52

5.1 Hepatitis A 52

5.2 Hepatitis B 54

5.3 Hepatitis D 95

5.4 Hepatitis E 98

6 Dormant Projects 101

6.1 Hepatitis A 101

6.2 Hepatitis B 102

6.3 Hepatitis D 108

6.4 Hepatitis E 108

7 Discontinued Products 109

7.1 Hepatitis B 109

8 Product Development Milestones 110

8.1 Hepatitis B 110

8.2 Hepatitis D 122

8.3 Hepatitis E 131

9 Appendix 132

9.1 Methodology 132

9.2 Coverage 132

9.3 Secondary Research 132

9.4 Primary Research 132

9.5 Expert Panel Validation 132

9.6 Contact Us 133

9.7 Disclaimer 133

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Number of Products under Development for Hepatitis A 9

Figure 2: Number of Products under Development by Companies, Hepatitis A 10

Figure 3: Number of Products under Development for Hepatitis B 12

Figure 4: Number of Products under Development by Companies, Hepatitis B 13

Figure 5: Number of Products under Development by Universities/Institutes, Hepatitis B 17

Figure 6: Number of Products under Development for Hepatitis D 27

Figure 7: Number of Products under Development by Companies, Hepatitis D 28

Figure 8: Number of Products under Development for Hepatitis E 30

Figure 9: Number of Products under Development by Companies, Hepatitis E 31

Figure 10: Number of Products by Stage and Routes of Administration, Hepatitis A 33

Figure 11: Number of Products by Molecule Types, Hepatitis A 34

Figure 12: Number of Products by Stage and Molecule Types, Hepatitis A 34

Figure 13: Number of Products by Top 10 Targets, Hepatitis B 35

Figure 14: Number of Products by Stage and Top 10 Targets, Hepatitis B 36

Figure 15: Number of Products by Top 10 Mechanism of Actions, Hepatitis B 38

Figure 16: Number of Products by Stage and Top 10 Mechanism of Actions, Hepatitis B 38

Figure 17: Number of Products by Routes of Administration, Hepatitis B 40

Figure 18: Number of Products by Stage and Routes of Administration, Hepatitis B 41

Figure 19: Number of Products by Top 10 Molecule Types, Hepatitis B 42

Figure 20: Number of Products by Stage and Top 10 Molecule Types, Hepatitis B 42

Figure 21: Number of Products by argets, Hepatitis D 44

Figure 22: Number of Products by Stage and Targets, Hepatitis D 44

Figure 23: Number of Products by Mechanism of Actions, Hepatitis D 45

Figure 24: Number of Products by Stage and Mechanism of Actions, Hepatitis D 46

Figure 25: Number of Products by Routes of Administration, Hepatitis D 47

Figure 26: Number of Products by Stage and Routes of Administration, Hepatitis D 47

Figure 27: Number of Products by Molecule Types, Hepatitis D 48

Figure 28: Number of Products by Stage and Molecule Types, Hepatitis D 49

Figure 29: Number of Products by Molecule Types, Hepatitis E 50

Figure 30: Number of Products by Stage and Molecule Types, Hepatitis E 51

1.1 List of Tables

Table 1: Number of Products under Development for Hepatitis A 9

Table 2: Number of Products under Development by Companies, Hepatitis A 10

Table 3: Number of Products under Development by Universities/Institutes, Hepatitis A 11

Table 4: Products under Development by Companies, Hepatitis A 11

Table 5: Products under Development by Universities/Institutes, Hepatitis A 11

Table 6: Number of Products under Development for Hepatitis B 12

Table 7: Number of Products under Development by Companies, Hepatitis B 14

Table 8: Number of Products under Development by Universities/Institutes, Hepatitis B 17

Table 9: Products under Development by Companies, Hepatitis B 18

Table 10: Products under Development by Universities/Institutes, Hepatitis B 26

Table 11: Number of Products under Development for Hepatitis D 27

Table 12: Number of Products under Development by Companies, Hepatitis D 28

Table 13: Number of Products under Development by Universities/Institutes, Hepatitis D 29

Table 14: Products under Development by Companies, Hepatitis D 29

Table 15: Products under Development by Universities/Institutes, Hepatitis D 29

Table 16: Number of Products under Development for Hepatitis E 30

Table 17: Number of Products under Development by Companies, Hepatitis E 31

Table 18: Number of Products under Development by Universities/Institutes, Hepatitis E 32

Table 19: Products under Development by Companies, Hepatitis E 32

Table 20: Products under Development by Universities/Institutes, Hepatitis E 32

Table 21: Number of Products by Stage and Route of Administration, Hepatitis A 33

Table 22: Number of Products by Stage and Molecule Type, Hepatitis A 35

Table 23: Number of Products by Stage and Target, Hepatitis B 36

Table 24: Number of Products by Stage and Mechanism of Action, Hepatitis B 39

Table 25: Number of Products by Stage and Route of Administration, Hepatitis B 41

Table 26: Number of Products by Stage and Molecule Type, Hepatitis B 43

Table 27: Number of Products by Stage and Target, Hepatitis D 45

Table 28: Number of Products by Stage and Mechanism of Action, Hepatitis D 46

Table 29: Number of Products by Stage and Route of Administration, Hepatitis D 48

Table 30: Number of Products by Stage and Molecule Type, Hepatitis D 49

Table 31: Number of Products by Stage and Target, Hepatitis E 49

Table 32: Number of Products by Stage and Mechanism of Action, Hepatitis E 50

Table 33: Number of Products by Stage and Route of Administration, Hepatitis E 50

Table 34: Number of Products by Stage and Molecule Type, Hepatitis E 51

Table 35: Hepatitis A-Pipeline by Beijing Minhai Biotechnology Co Ltd 52

Table 36: Hepatitis A-Pipeline by Cadila Healthcare Ltd 52

Table 37: Hepatitis A-Pipeline by China National Pharmaceutical Group Corp 53

Table 38: Hepatitis A-Pipeline by Indian Immunologicals Ltd 53

Table 39: Hepatitis A-Pipeline by Sinovac Biotech Ltd 54

Table 40: Hepatitis B-Pipeline by Abivax SA 54

Table 41: Hepatitis B-Pipeline by AiCuris GmbH & Co KG 55

Table 42: Hepatitis B-Pipeline by AIMM Therapeutics BV 55

Table 43: Hepatitis B-Pipeline by Akshaya Bio Inc 56

Table 44: Hepatitis B-Pipeline by Alnylam Pharmaceuticals Inc 56

Table 45: Hepatitis B-Pipeline by Altimmune Inc 57

Table 46: Hepatitis B-Pipeline by Altravax Inc 57

Table 47: Hepatitis B-Pipeline by Amarna Therapeutics BV 58

Table 48: Hepatitis B-Pipeline by Arbutus Biopharma Corp 58

Table 49: Hepatitis B-Pipeline by Arcturus Therapeutics Ltd 59

Table 50: Hepatitis B-Pipeline by Arrowhead Pharmaceuticals Inc 59

Table 51: Hepatitis B-Pipeline by Ascentage Pharma Group Corp Ltd 60

Table 52: Hepatitis B-Pipeline by Assembly Biosciences Inc 60

Table 53: Hepatitis B-Pipeline by Aucta Pharmaceuticals LLC 61

Table 54: Hepatitis B-Pipeline by Beijing Kawin Technology Share-Holding Co Ltd 61

Table 55: Hepatitis B-Pipeline by Beijing Minhai Biotechnology Co Ltd 62

Table 56: Hepatitis B-Pipeline by Benitec Biopharma Ltd 62

Table 57: Hepatitis B-Pipeline by Biological E Ltd 63

Table 58: Hepatitis B-Pipeline by BioStar Pharmaceuticals Inc 63

Table 59: Hepatitis B-Pipeline by Biotron Ltd 64

Table 60: Hepatitis B-Pipeline by Bolder Biotechnology Inc 64

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Abivax SA

AiCuris GmbH & Co KG

AIMM Therapeutics BV

Akshaya Bio Inc

Alnylam Pharmaceuticals Inc

Altimmune Inc

Altravax Inc

Amarna Therapeutics BV

Arbutus Biopharma Corp

Arcturus Therapeutics Ltd

Arrowhead Pharmaceuticals Inc

Ascentage Pharma Group Corp Ltd

Assembly Biosciences Inc

Aucta Pharmaceuticals LLC

Beijing Kawin Technology Share-Holding Co Ltd

Beijing Minhai Biotechnology Co Ltd

Benitec Biopharma Ltd

Biological E Ltd

BioStar Pharmaceuticals Inc

Biotron Ltd

Bolder Biotechnology Inc

BrightGene Bio-Medical Technology Co Ltd

Bukwang Pharm Co Ltd

Cadila Healthcare Ltd

CaroGen Corp

Celltrion Inc

China National Pharmaceutical Group Corp

Chong Kun Dang Pharmaceutical Corp

Chongqing Zhifei Biological Products Co Ltd

Chromis Therapeutics Inc

Cocrystal Pharma Inc

ContraVir Pharmaceuticals Inc

CyTuVax BV

DelSiTech Ltd

Dicerna Pharmaceuticals Inc

Dong-A Socio Holdings Co Ltd

Ensemble Therapeutics Corp

Enyo Pharma SA

Excision BioTherapeutics Inc

F. Hoffmann-La Roche Ltd

GC Pharma

GeneCure LLC

GeoVax Labs Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Huons Global Co Ltd

Immunotope Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Intellia Therapeutics Inc

Ionis Pharmaceuticals Inc

ISA Pharmaceuticals BV

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Johnson & Johnson

Kainos Medicine Inc

Kineta Inc

LG Chem Ltd

Microbiotix Inc

MultiCell Technologies Inc

Oncolys BioPharma Inc

Pfenex Inc

PharmaEssentia Corp

Profarma

Profectus BioSciences Inc

Qilu Pharmaceutical Co Ltd

Replicor Inc

Rodos BioTarget GmbH

Samjin Pharm Co Ltd

Sanofi Pasteur SA

Scynexis Inc

Shantha Biotechnics Pvt Ltd

Sino Biopharmaceutical Ltd

Sinovac Biotech Ltd

Spring Bank Pharmaceuticals Inc

TCM Biotech International Corp

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Transgene SA

Vaccitech Ltd

Vaxine Pty Ltd

VBI Vaccines Inc

Vical Inc

ViroStatics srl

VLP Biotech Inc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand